The SAFE Prospective Registry

ConditionAtrial Fibrillation, Paroxysmal or Persistent

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18+

SponsorUniversity Hospital Ostrava

About this trial

Secretoneurin (SN) is a neuropeptide from the chromogranin family that influences intracellular calcium handling. SN suppresses calcium leakage from the sarcoplasmic reticulum through the ryanodine receptor. SN is a novel biomarker that has shown the potential to predict adverse arrhythmic events.

Eligibility criteria

Qualifiers

Atrial fibrillation (Afib); (paroxysmal, persistent)

Patients indicated for catheter ablation and/or electrical cardioversion

Signed informed consent

Disqualifiers

Longstanding or permanent atrial fibrillation

Severe mitral regurgitation

Heart failure with a permanently reduced ejection fraction

Cerebral ischaemic stroke in < 3 months

Trial design

Treatments tested in this trial

Catheter ablation and/or electrical cardioversion

Treatment groups

60 Participants

are divided into 1 treatment group

Sponsors and collaborators

University Hospital Ostrava

Lead sponsor

Source ClinicalTrials.gov